CVM Stock - CEL-SCI Corporation
Unlock GoAI Insights for CVM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $558,664 |
| Gross Profit | $-3,969,183 | $-3,958,334 | $-3,883,386 | $-499,000 | $540,824 |
| Gross Margin | N/A | N/A | N/A | N/A | 96.8% |
| Operating Income | $-26,352,474 | $-31,476,074 | $-36,062,793 | $-36,194,129 | $-28,985,055 |
| Net Income | $-26,920,465 | $-32,365,855 | $-38,267,691 | $-39,187,563 | $-32,223,336 |
| Net Margin | N/A | N/A | N/A | N/A | -5767.9% |
| EPS | $-13.50 | $-21.90 | $-26.70 | $-28.80 | $-26.40 |
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
Visit WebsiteEarnings History & Surprises
CVMEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q1 2026 | Jan 12, 2026 | — | — | — | — |
Q3 2025 | Aug 14, 2025 | — | $-1.36 | — | — |
Q2 2025 | May 14, 2025 | — | $-2.40 | — | — |
Q1 2025 | Jan 13, 2025 | $-0.10 | $-0.09 | +10.0% | ✓ BEAT |
Q4 2024 | Dec 27, 2024 | $-0.11 | $-0.16 | -45.5% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-0.13 | $-0.14 | -7.7% | ✗ MISS |
Q2 2024 | May 16, 2024 | $-0.14 | $-0.14 | 0.0% | = MET |
Q1 2024 | Feb 14, 2024 | $-0.14 | $-0.14 | 0.0% | = MET |
Q4 2023 | Dec 22, 2023 | $-0.16 | $-0.16 | 0.0% | = MET |
Q3 2023 | Aug 11, 2023 | $-0.17 | $-0.19 | -11.8% | ✗ MISS |
Q2 2023 | May 12, 2023 | $-0.17 | $-0.19 | -11.8% | ✗ MISS |
Q1 2023 | Feb 14, 2023 | $-0.21 | $-0.18 | +14.3% | ✓ BEAT |
Q4 2022 | Dec 28, 2022 | $-0.20 | $-0.21 | -5.0% | ✗ MISS |
Q3 2022 | Aug 15, 2022 | $-0.15 | $-0.23 | -53.3% | ✗ MISS |
Q2 2022 | May 16, 2022 | $-0.16 | $-0.23 | -43.8% | ✗ MISS |
Q1 2022 | Feb 14, 2022 | — | $-0.20 | — | — |
Q4 2021 | Dec 22, 2021 | $-0.10 | $-0.19 | -90.0% | ✗ MISS |
Q3 2021 | Aug 16, 2021 | $-0.13 | $-0.25 | -92.3% | ✗ MISS |
Q2 2021 | May 18, 2021 | $-0.19 | $-0.20 | -5.3% | ✗ MISS |
Latest News
CEL-SCI shares are trading lower after the company announced a $10 million public offering.
📉 NegativeReported Earlier, CEL-SCI Prices $10M Public Offering Of 1,111,200 Common Shares At $9.00 Each To Fund Multikine Development
➖ NeutralCEL-SCI shares drop on proposed public offering
📉 NegativeCEL-SCI Announces Proposed Public Offering; No Size Or Amount Disclosed
➖ NeutralCEL-SCI plummets 44%, prices $5M stock offering
📉 NegativeFrequently Asked Questions about CVM
What is CVM's current stock price?
What is the analyst price target for CVM?
What sector is CEL-SCI Corporation in?
What is CVM's market cap?
Does CVM pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CVM for comparison